PLANEGG-MARTINSRIED (dpa-AFX) - The biotech company Formycon has been granted approval to market its biosimilar for the eye medication Lucentis in Brazil. Lucentis is manufactured by the Swiss pharmaceutical company Novartis. The Brazilian regulatory authority has given the green light to its biotechnologically manufactured generic product called Ranivisio (active ingredient ranibizumab). Other countries in Central and South America are expected to follow, with market approvals already granted, the SDax-listed biosimilar specialist announced on Thursday.
The active ingredient ranibizumab is used to treat various eye diseases, such as wet age-related macular degeneration (AMD). In Brazil, the largest healthcare market in the region, Formycon will sell its Lucentis biosimilar through the local pharmaceutical company Biomm. The launch is planned for the final quarter of 2025, Formycon added./tav/mis
